PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Hydrocortisone

Drugs in development · updated 30 October 2026

Hydrocortisone: clinical trials and development status

Other names and codes: Khindivi, Alkindi Sprinkle, Cortifoam, Cortenema

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 3 November 2011

As of 30 October 2026 Hydrocortisone is in 41 active clinical trials (recruiting or ongoing, phases I–III) for 43 diseases. The most advanced phase is III.

41Active trials
IIIMost advanced phase
43Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Hydrocortisone and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 43 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Precursor lymphoblastic lymphoma/leukemiaIII8NCT03007147
Acute biphenotypic leukaemiaIII7NCT03007147
Burkitt lymphomaIII4NCT02101853
Precursor T-cell lymphoblastic leukemiaIII4NCT02112916
Acute myeloid leukemiaIII3NCT04293562
SepsisIII3NCT07332325
Diabetes insipidusIII2NCT04591990
Prostatic NeoplasmsIII2NCT06136650
Community-acquired pneumoniaIII1NCT02735707
COVID-19III1NCT02735707
InfluenzaIII1NCT02735707
Lung diseaseIII1NCT02735707
LymphomaII–III1NCT07072585
PneumoniaIII1NCT02735707
Respiratory diseaseIII1NCT02735707
Respiratory tract infectionIII1NCT02735707
Septic shockIII1NCT03401398
TuberculosisIII1NCT07332325
Down syndromeII2NCT04546399
Pancreatic neoplasmII2NCT07895498
T-cell lymphomaII2NCT06390319
Diffuse large B-cell lymphomaII1NCT07763210
Lymphoma, B-Cell, Marginal ZoneII1NCT07763210
Mantle cell lymphomaII1NCT07763210
NeoplasmII1NCT03286634
Non-Hodgkin lymphomaII1NCT07763210
Opioid-related disordersII1NCT04231708
PancreatitisII1NCT05160506
Atopic dermatitisI1NCT06504160
B-cell lymphomaI1NCT05476770

Everything on Hydrocortisone

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch